Healthcare >> Sector Roundtables >> November 17, 2008
George Huang is a biotechnology analyst at Stansberry & Associates, an
independent equity research firm. His coverage universe includes small- to mid-
cap biotechs with a strong focus in the infectious diseases, metabolic diseases,
autoimmunity, oncology and platform technologies. His research and trading
strategies are featured in two publications (The FDA Report, Phase 1 Investor).
He was the Pollard Scholar and received his PhD in Cellular and Molecular
Medicine from Johns Hopkins University and Bachelor of Science degree in Biology
from University of British Columbia. Profile
Debjit Chattopadhyay joined Boenning & Scattergood, Inc., in August 2006 and
covers the medical technology sector. He covers biotechnology,
biopharmaceuticals and medical device companies. He is particularly interested
in rapidly developing research areas like RNA therapeutics, stem cells and
angiogenesis. From a diagnostic perspective, He follows companies developing
bioarray technologies. Before joining Boenning, he was a Research Fellow at
Memorial Sloan Kettering Cancer Center. At Sloan, he was actively involved in
the development of novel targeted therapeutics, vaccines and initiated research
in nanobiotechnology. He holds a PhD from the University of Connecticut. Profile
Charles C. Duncan joined JMP Securities LLC in November 2002 as a Managing
Director and Senior Research Analyst covering biotechnology. Prior to joining
JMP, he had served as Director of U.S. Equities and as a biotechnology analyst
at Dresdner Kleinwort Wasserstein Securities from July 2001. He previously spent
a year at Prudential Vector Healthcare Group and its predecessor, Vector
Securities International, as a Senior Vice President following biotechnology and
genomics. He began his equity research careerat Tucker Anthony Cleary Gull,
where he covered drug development and therapeutics from March 1997 through May
2000. He is a member of the Association for Investment Management Research, the
Denver Society of Security Analysts, the American Association for the
Advancement of Science and the Society of Neuroscience. He received a PhD in
Pharmaceutical sciences from the University of Colorado and a BS degree in
Zoology and Molecular Biology from the University of Wisconsin, Madison. Profile
this treacherous period we've been going through?
Mr. Chattopadhyay: Well, it depends. If you really stratify
